Published in Clin Exp Metastasis on June 24, 2015
Genome-wide analysis of long noncoding RNA (lncRNA) expression in colorectal cancer tissues from patients with liver metastasis. Cancer Med (2016) 0.86
S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction. Cancers (Basel) (2016) 0.79
Liver metastases: Microenvironments and ex-vivo models. Exp Biol Med (Maywood) (2016) 0.78
CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells. Oncotarget (2016) 0.78
MACC1 upregulation promotes gastric cancer tumor cell metastasis and predicts a poor prognosis. J Zhejiang Univ Sci B (2016) 0.77
The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget (2016) 0.76
ELL targets c-Myc for proteasomal degradation and suppresses tumour growth. Nat Commun (2016) 0.76
Sciellin mediates mesenchymal-to-epithelial transition in colorectal cancer hepatic metastasis. Oncotarget (2016) 0.75
Up-regulated CKS2 promotes tumor progression and predicts a poor prognosis in human colorectal cancer. Am J Cancer Res (2015) 0.75
Vascular Invasion and Stromal S100A4 Expression at the Invasive Front of Colorectal Cancer are Novel Determinants and Tumor Prognostic Markers. J Cancer (2017) 0.75
miR-133b suppresses metastasis by targeting HOXA9 in human colorectal cancer. Oncotarget (2017) 0.75
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 7.99
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol (2002) 5.73
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell (2010) 5.47
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16
Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 4.12
A phosphatase associated with metastasis of colorectal cancer. Science (2001) 3.86
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol (2013) 3.76
Protein-tyrosine phosphatases and cancer. Nat Rev Cancer (2006) 3.65
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med (2008) 3.00
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet (1999) 2.84
The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol (2011) 2.83
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res (1988) 2.67
Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract (1998) 2.63
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell (2011) 2.45
Functions of S100 proteins. Curr Mol Med (2013) 2.43
L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol (2005) 2.39
In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res (1988) 2.36
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ (2010) 2.09
PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res (2003) 1.94
Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J (2006) 1.93
The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 1.82
Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays (2002) 1.76
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
PRL-3 expression in metastatic cancers. Clin Cancer Res (2003) 1.73
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res (1995) 1.71
Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev (1994) 1.69
Analysing uncharted transcriptomes with SAGE. Trends Genet (2000) 1.68
Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members. J Biol Chem (2007) 1.64
Tissue inhibitors of metalloproteinases. Genome Biol (2011) 1.62
Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res (2006) 1.61
Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer (2013) 1.56
Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol (2000) 1.56
PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev (2008) 1.54
The lipase gene family. J Lipid Res (2002) 1.54
Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev (1991) 1.51
Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology (2009) 1.49
Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene (1997) 1.48
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis (2009) 1.46
The neural cell adhesion molecule L1 interacts with the AP-2 adaptor and is endocytosed via the clathrin-mediated pathway. J Neurosci (1998) 1.46
Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res (2007) 1.46
Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol (2009) 1.44
Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer (2010) 1.43
Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther (2008) 1.41
Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst (1986) 1.38
Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res (2006) 1.35
PRL-3 phosphatase and cancer metastasis. J Cell Biochem (2010) 1.32
MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer (2012) 1.30
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res (2000) 1.27
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol (2006) 1.26
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest (2011) 1.23
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol (2007) 1.20
Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene (2012) 1.20
L1-CAM in cancerous tissues. Expert Opin Biol Ther (2008) 1.19
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res (2001) 1.19
Targeting TGF-β signaling in cancer. Expert Opin Ther Targets (2013) 1.16
Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci (2010) 1.15
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther (2008) 1.15
The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene (2007) 1.14
The Trop-2 signalling network in cancer growth. Oncogene (2012) 1.14
Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver. Hepatology (1996) 1.12
Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer (2008) 1.12
MACC1 - more than metastasis? Facts and predictions about a novel gene. J Mol Med (Berl) (2009) 1.11
L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol (2007) 1.10
Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem (2013) 1.09
Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS One (2012) 1.06
Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis. Cancer Res (2010) 1.06
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest (2013) 1.04
Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res (2002) 1.02
Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis (2008) 1.02
Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol (2005) 1.01
Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol (2008) 1.01
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res (2007) 1.00
Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer (2010) 0.99
Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res (2010) 0.98
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett (2011) 0.97
Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta (2009) 0.96
Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis (2011) 0.95
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget (2012) 0.94
Small interfering RNA-mediated downregulation of beta-catenin inhibits invasion and migration of colon cancer cells in vitro. Med Sci Monit (2012) 0.94
AID and Apobec3G haphazard deamination and mutational diversity. Cell Mol Life Sci (2012) 0.93
On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1α, and miR-210. Front Pharmacol (2012) 0.93
Alternative use of a mini exon of the L1 gene affects L1 binding to neural ligands. J Biol Chem (2001) 0.92
A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent. J Org Chem (2004) 0.91
Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori (2012) 0.90
Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res (2006) 2.20
Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res (2006) 1.35
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
Systematic comparison of SCOP and CATH: a new gold standard for protein structure analysis. BMC Struct Biol (2009) 1.16
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem (2006) 1.13
Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem (2004) 1.10
Protein structure alignment considering phenotypic plasticity. Bioinformatics (2008) 1.09
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res (2002) 1.04
Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res (2002) 1.02
Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics (2010) 1.00
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett (2011) 0.97
O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging (2002) 0.97
Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma. Mol Cancer Res (2008) 0.96
Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis (2011) 0.95
A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem (2010) 0.95
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des (2003) 0.93
On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1α, and miR-210. Front Pharmacol (2012) 0.93
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett (2002) 0.92
Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells. Mol Cancer (2012) 0.88
Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target. Front Pharmacol (2012) 0.86
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat (2010) 0.86
Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology (2014) 0.86
Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer (2014) 0.86
Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. J Gene Med (2004) 0.85
Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thromb Haemost (2005) 0.85
New opportunities in drug design of metalloproteinase inhibitors: combination between structure-function experimental approaches and systems biology. Expert Opin Drug Discov (2011) 0.85
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Recent Results Cancer Res (2003) 0.83
In vivo analysis of retroviral gene transfer to chondrocytes within collagen scaffolds for the treatment of osteochondral defects. Biomaterials (2007) 0.83
Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. Clin Exp Metastasis (2013) 0.82
Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. Cancer Res (2005) 0.82
Tetraspanin CD63 acts as a pro-metastatic factor via β-catenin stabilization. Int J Cancer (2014) 0.82
Viral transcriptome analysis of feline immunodeficiency virus infected cells using second generation sequencing technology. Vet Immunol Immunopathol (2011) 0.81
The influence of the stable expression of BMP2 in fibrin clots on the remodelling and repair of osteochondral defects. Biomaterials (2009) 0.81
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α. Clin Exp Metastasis (2010) 0.81
Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems. Biol Chem (2003) 0.80
Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line. J Biol Chem (2010) 0.80
Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif. Angew Chem Int Ed Engl (2014) 0.79
The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth. Front Pharmacol (2012) 0.79
Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases. Mol Cancer Res (2008) 0.79
Full-length L1CAM and not its Δ2Δ27 splice variant promotes metastasis through induction of gelatinase expression. PLoS One (2011) 0.79
PRIME: a graphical interface for integrating genomic/proteomic databases. Proteomics (2005) 0.79
Improving structure alignment-based prediction of SCOP families using Vorolign kernels. Bioinformatics (2010) 0.78
Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15. Int J Cancer (2014) 0.78
Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver. Hum Gene Ther (2008) 0.78
Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine. Cell Biochem Funct (2011) 0.77
Selective inhibition of the immunoproteasome by ligand-induced crosslinking of the active site. Angew Chem Int Ed Engl (2014) 0.77
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. J Cell Mol Med (2010) 0.76
Efficient and stable gene transfer of growth factors into chondrogenic cells and primary articular chondrocytes using a VSV.G pseudotyped retroviral vector. Biomaterials (2008) 0.76
Correction: Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS Pathog (2016) 0.75
Placental expression of proteases and their inhibitors in patients with HELLP syndrome. Biol Chem (2009) 0.75
The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells. Stem Cells Dev (2013) 0.75
Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors. Biol Chem (2003) 0.75